Sigyn Therapeutics (SIGY) Stock Analysis & Winston Score

Winston Score History

Sigyn Therapeutics is a small biotech company working on a medical device designed to clean harmful substances out of a patient's blood. The device, called Sigyn Therapy, is meant to treat serious conditions like sepsis, drug overdoses, and viral infections by filtering out toxins and inflammatory molecules during a process similar to dialysis. The company is in the early development stage and has not yet received regulatory approval to sell its product.

Sigyn Therapeutics does not currently generate meaningful revenue, which explains its deeply negative operating margin. It is a pre-revenue company based in the United States that funds its operations primarily through equity financing, meaning it sells shares to raise cash. The main risk facing the business is significant: it must successfully complete clinical trials and obtain FDA clearance before it can sell anything, and there is no guarantee that will happen on any particular timeline or at all.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+0.0% YoY

YoY Growth Rate

Slow EPS growth

Insider Activity

44.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$265 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Sigyn Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial